IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera ...
The Victoria Advocate20d
Moderna R&D Day Highlights Progress and Strategic Priorities
[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 ...
TheDerrick.com1d
Book Review: 'The Last Dream,' short stories scattered with the seeds of Pedro Almodovar films
The seeds of Spanish filmmaker Pedro Almodóvar’s later cinematic work are scattered throughout the pages of “The Last Dream,” ...
Moderna, Inc.: Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...